Mosaic ImmunoEngineering (CPMV) Income from Discontinued Operations (2011 - 2015)
Mosaic ImmunoEngineering (CPMV) posted Income from Discontinued Operations of -$6107.0 for Q2 2015, down 730.24% on a QoQ basis from $969.0 in Q1 2015, and down 112.6% year-over-year from $48477.0 in Q2 2014.
Analysis
Mosaic ImmunoEngineering (CPMV) Income from Discontinued Operations (2011 - 2015) Analysis & Trends
Mosaic ImmunoEngineering has reported Income from Discontinued Operations for 5 years, with the latest figure at -$6107.0 in Q2 2015.
- On a quarterly basis, Income from Discontinued Operations fell 112.6% year-over-year to -$6107.0 in Q2 2015; TTM through Feb 2016 was -$6107.0, a 111.59% decrease from a year earlier, with the FY2015 full-year figure at -$1873.0, down 102.1% from the prior year.
- Income from Discontinued Operations was -$6107.0 for Q2 2015 at Mosaic ImmunoEngineering, down from $969.0 in the prior quarter.
- The five-year high for Income from Discontinued Operations was $2.5 million in Q2 2011, with the low at -$5.1 million in Q1 2011.
- Average Income from Discontinued Operations over 5 years is -$227388.9, with a median of $465.0 recorded in 2014.
- The sharpest annual moves came in 2013 and 2015: Income from Discontinued Operations jumped 4820.23% in 2013, then plunged 112.6% in 2015.
- Over 5 years, Income from Discontinued Operations stood at -$329919.0 in 2011, then surged by 100.33% to $1078.0 in 2012, then slumped by 79.13% to $225.0 in 2013, then soared by 106.67% to $465.0 in 2014, then sank by 1413.33% to -$6107.0 in 2015.
- The last three Income from Discontinued Operations figures came in at -$6107.0 (Q2 2015), $969.0 (Q1 2015), and $465.0 (Q4 2014), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Discontinued) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Mosaic ImmunoEngineering | 434,528.21 | 434,528.21 | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| May 31, 2015 | -6,107.00 |
| Feb 28, 2015 | 969.00 |
| Nov 30, 2014 | 465.00 |
| Aug 31, 2014 | 2,800.00 |
| May 31, 2014 | 48,477.00 |
| Nov 30, 2013 | 225.00 |
| Aug 31, 2013 | 40,358.00 |
| May 31, 2013 | 10,680.00 |
| Feb 28, 2013 | 1,248.00 |
| Nov 30, 2012 | 1,078.00 |
| Aug 31, 2012 | -855.00 |
| May 31, 2012 | -134,451.00 |
| Feb 29, 2012 | -566,722.00 |
| Nov 30, 2011 | -329,919.00 |
| Aug 31, 2011 | -332,627.00 |
| May 31, 2011 | 2.47 Mn |
| Feb 28, 2011 | -5.07 Mn |